[
    {
        "title": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.",
        "paper_uid": "d783a7f7",
        "reference": "Smolen JS. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): A randomised controlled trial. The Lancet. 2013;381(9870):918.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.",
        "paper_uid": "0570bda2",
        "reference": "Emery P. Sustained Remission with Etanercept Tapering in Early Rheumatoid Arthritis. New England Journal of Medicine. 2014;371:1781-92.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.",
        "paper_uid": "506166f3",
        "reference": "Weinblatt ME. A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis. Arthritis & Rheumatology. 2017;69(10):1937.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.",
        "paper_uid": "60bbc82c",
        "reference": "van Vollenhoven RF. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis BMJ. 2016;75:52-8.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.",
        "paper_uid": "48d24eba",
        "reference": "Strand V. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. International Journal of Clinical Rheumatology. 2015;10(5):317.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    },
    {
        "title": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.",
        "paper_uid": "4e39bd02",
        "reference": "Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, et al. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. Journal of Rheumatology. 2016;43(7):1268.",
        "save_folder_path": null,
        "study_design": "Randomized Controlled Trial"
    }
]